Genetics Research Breakthroughs

💬 "If you don't have celiac disease, you don't need to avoid gluten." If only you had a dime for every time a healthcare provider said this. It turns out that celiac disease isn't the only autoimmune condition that can be caused or exacerbated by gluten consumption. 🧬 Celiac disease is considered a hereditary genetic condition, characterized by the presence of certain genetic alleles such as HLA-DQ2 and HLA-DQ8. But several other autoimmune diseases are also linked to gluten sensitivity, including type 1 diabetes, rheumatoid arthritis, and Sjögren's syndrome. 🍏 Nutrigenomics provides a genetic understanding for how common dietary components, such as gluten, affect our health and disease status. Let’s examine the interplay between gluten and various genes associated with autoimmune conditions. The genes implicated in these conditions fall into three main categories: 1️⃣ HLA genes (in pink): These are part of our immune system and play a crucial role in how our bodies recognize and respond to foreign substances, including gluten. Examples include: 📌 HLA-DQ2 and HLA-DQ8: Strongly associated with celiac disease 📌 HLA-DR3 and HLA-DR5: Linked to autoimmune thyroid diseases 2️⃣ Non-HLA genes (in blue): These include genes involved in immune regulation, intestinal barrier function, and cellular processes that can influence autoimmune responses. Examples include: 📌 IL-2 and IL-21: Involved in regulating immune responses 📌 INS: Insulin gene, associated with type 1 diabetes 📌 FOXP3: Important for the function of regulatory T cells 3️⃣ Shared genes (in orange): These genes are associated with multiple autoimmune conditions, suggesting common pathways in autoimmune dysfunction. Examples include: 📌 CTLA4: Regulates T cell responses & linked to several autoimmune diseases 📌 STAT4: Involved in immune cell signaling & associated with multiple autoimmune conditions 📌 MYO9B: Affects intestinal permeability & linked to celiac disease, rheumatoid arthritis, and lupus While not everyone with these genes will develop gluten sensitivity or an autoimmune condition, this research is a reminder that nutrition isn't one-size-fits-all, and some individuals might benefit from reducing gluten intake even in the absence of celiac diagnosis. Always consult with a healthcare professional before making significant dietary changes, but don't be afraid to advocate for yourself if you suspect gluten sensitivity. Your body's response to food is unique, and recognizing that is key to improving health outcomes.

Last week I stood in front of 50 bioinformaticians and ran a pharmacogenomics analysis in under one second. No cloud. No data leaving the room. Within 24 hours, a researcher I'd never met submitted a pull request adding a nutrigenomics skill I hadn't planned. That's how ClawBio started. The problem: general-purpose AI is powerful but blind to biology. It hallucinates star allele calls. It uses outdated CPIC guidelines. And you can't send patient genomes to a cloud API. ClawBio fixes this. It's a skill library that gives AI agents real bioinformatics expertise — pharmacogenomics, equity scoring, metagenomics, nutrigenomics — all running locally on your machine. What we shipped in one week: - 7 production skills (PharmGx, Equity Scorer, NutriGx, Metagenomics, and more) - 57 automated tests, CI on 3 Python versions - 1 community contribution merged in 24 hours - Published on ClawHub registry What I learned: 1. Methodology before code — a detailed spec is itself useful 2. Local-first isn't a limitation, it's the moat 3. One unsolicited PR proves architecture more than any benchmark 4. Tests are trust signals — it's why I merged fast 8 more skills are waiting for contributors: VCF annotation, scRNA-seq, protein structure, lit synthesis. If you work with genomic data and want to build: github.com/ClawBio/ClawBio MIT licensed. Every analysis ships with a reproducibility bundle. #Bioinformatics #AI #Genomics #OpenSource #Pharmacogenomics #HealthEquity

Half a million genomes. 1.5 billion variants. One breakthrough: we are all truly unique. Twenty years ago, the Human Genome Project took 13 years and $2.7B to sequence a single genome. Today? We can sequence a genome in less than 24 hours for under $1,000. Last week, UK Biobank released 490,640 whole genomes — the largest genetic dataset ever (Nature, 2025). What did we learn? • Each person carries 4–5 million variants • 76% appear in fewer than 10 people — your genome is almost entirely yours • 1 in 10 carries clinically actionable mutations where doctors can intervene today (e.g., BRCA1/2 for cancer, LDLR for heart disease) Why it matters: • Previous genetic tests captured ~6% of human variation. This dataset reveals 40× more • In non-coding regions — the biological switches controlling genes — researchers found 63 new disease associations • Adding 31,785 non-European genomes uncovered 82 disease links invisible in Eurocentric studies From genetics to health impact This transforms medicine today: • Prevention - Polygenic risk scores flag disease decades before symptoms • Diagnosis - Rare disease patients waiting years for answers finally find them • Treatment - Pharmacogenomics matches the right drug, right dose, to your genome The next frontier: genetics + everything else Genetics is the hardware. Health is the software running in real time. Your DNA is fixed, but biology is dynamic, shaped by: • Epigenetics: how environment and lifestyle switch genes on/off • Proteomics & metabolomics: molecular signals revealing your current health state • Digital biomarkers: continuous data from stress, sleep, glucose, heart rate • Stress biology & neuroendocrine signaling: how cortisol and brain-body responses reshape your health trajectory Layer these dynamic signals onto genetic foundations, power them with AI, and you create living health models, not just predicting disease, but understanding when, why, and how it manifests in YOU. The critical question? We've spent decades treating the "average patient" — who doesn't exist. Now we can better see each person as they truly are: biologically unique, dynamically changing, infinitely complex. The healthcare winners of the next decade won't just collect data: they'll integrate genetics, epigenetics, molecular and phenotypic tests, lifestyle, stress biology, and digital signals to deliver truly personalized, preventive care at scale. There is no "normal" genome, only 8 billion unique experiments in being human. And we just decoded the first half million. 👉 Which excites you more: knowing your genetic blueprint, or understanding how your daily choices rewrite it?

Synthetic biology is - quite literally - our future. A goundbreaking new biological foundation model Evo2 achieves state-of-the-art prediction of genetic variation impacts and generates coherent genome sequences, spanning all domains of life. A diverse team from leading research institutions including Arc Institute Stanford University NVIDIA University of California, Berkeley trained the model on 9.3 trillion DNA base pairs and has fully shared all code, parameters, and data. A few highlights from the paper (link in comments) 🔬 Zero-shot prediction achieves state-of-the-art accuracy in genetic variant interpretation. Evo 2 can predict the functional consequences of genetic mutations across all domains of life without specialized training. It surpasses existing models in assessing the pathogenicity of both coding and noncoding variants, including BRCA1 cancer-linked mutations. This generalist capability suggests Evo 2 could revolutionize genetic disease research, reducing reliance on expensive, manually curated datasets. 🛠 Genome-scale generation paves the way for synthetic life design. Evo 2 can generate full-length genome sequences with realistic structure and function, including mitochondrial genomes, bacterial chromosomes, and yeast DNA. Unlike prior models, Evo 2 ensures natural sequence coherence, improving synthetic biology applications like engineered microbes or artificial organelles. This sets the stage for programmable biology at an unprecedented scale. 🧬 Unprecedented long-context understanding revolutionizes genomic analysis. Evo 2 operates with a context window of up to 1 million nucleotides—far beyond the capabilities of previous models—allowing it to analyze genomic features across vast distances. This ability enables it to accurately identify regulatory elements, exon-intron boundaries, and structural components critical for understanding genome function. Its long-context recall is a major breakthrough for interpreting complex biological sequences. 🎛 Inference-time search enables controllable epigenomic design. Evo 2’s generative abilities extend beyond raw DNA sequence to epigenomic features, allowing researchers to design sequences with specific chromatin accessibility patterns. This approach successfully encoded Morse code messages into synthetic epigenomes, demonstrating a new method for controlling gene regulation via AI. This could lead to breakthroughs in gene therapy and epigenetic engineering. 🔮 Future potential: Toward AI-driven biological design and virtual cell modeling. Evo 2 represents a major leap toward AI-powered genomic engineering. Future iterations could integrate additional biological layers—such as transcriptomics and proteomics—to create virtual cell models that simulate complex cellular behaviors. This could revolutionize drug discovery, genetic therapy, and even synthetic life creation.

Research from Harvard & MIT used AI to unlock molecular insights in cancer pathology. Foundation models are revolutionizing computational pathology. But, most struggle to analyze entire whole-slide images (WSIs) and incorporate molecular data. 𝗧𝗛𝗥𝗘𝗔𝗗𝗦 𝗶𝗻𝘁𝗿𝗼𝗱𝘂𝗰𝗲𝘀 𝗮 𝗺𝘂𝗹𝘁𝗶𝗺𝗼𝗱𝗮𝗹 𝗳𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻 𝗺𝗼𝗱𝗲𝗹 𝘁𝗵𝗮𝘁 𝗹𝗲𝗮𝗿𝗻𝘀 𝗳𝗿𝗼𝗺 𝗯𝗼𝘁𝗵 𝗵𝗶𝘀𝘁𝗼𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆 𝘀𝗹𝗶𝗱𝗲𝘀 𝗮𝗻𝗱 𝗺𝗼𝗹𝗲𝗰𝘂𝗹𝗮𝗿 𝗽𝗿𝗼𝗳𝗶𝗹𝗲𝘀. • 𝗣𝗿𝗲𝘁𝗿𝗮𝗶𝗻𝗲𝗱 𝗼𝗻 𝟰𝟳,𝟭𝟳𝟭 𝗛&𝗘-𝘀𝘁𝗮𝗶𝗻𝗲𝗱 𝗪𝗦𝗜𝘀 𝘄𝗶𝘁𝗵 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗮𝗻𝗱 𝘁𝗿𝗮𝗻𝘀𝗰𝗿𝗶𝗽𝘁𝗼𝗺𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗲𝘀, the largest dataset of its kind. • Enabled state-of-the-art survival prediction, identifying high-risk patients with up to 8.9% higher accuracy than previous models. • 𝗘𝘅𝗰𝗲𝗹𝗹𝗲𝗱 𝗶𝗻 𝗹𝗼𝘄-𝗱𝗮𝘁𝗮 𝘀𝗰𝗲𝗻𝗮𝗿𝗶𝗼𝘀, achieving near-clinical accuracy with just 4 training samples per class. • Introduced “molecular prompting”, allowing AI to classify cancer types and mutations without task-specific training. I like that the architecture of THREADS is notably modular. It begins with an ROI encoder based on CONCHV1.5 (a ViT-L model fine-tuned with vision–language data) to extract patch features. The patch features are then aggregated into a slide-level embedding via an attention-based multiple instance learning (ABMIL) slide encoder. In parallel, distinct encoders for transcriptomic data (a modified scGPT) and genomic data (a multi-layer perceptron) create molecular embeddings. This design not only enables integration of heterogeneous data types but also achieves remarkable parameter efficiency. For instance, THREADS is reported to be 4× smaller than PRISM and 7.5× smaller than GIGAPATH, yet outperforms them on 54 oncology tasks. Here's the awesome work: https://lnkd.in/g5y5HFuV Congrats to Faisal Mahmood, Anurag Vaidya, Andrew Zhang, Guillaume Jaume, and co! I post my takes on the latest developments in health AI – 𝗰𝗼𝗻𝗻𝗲𝗰𝘁 𝘄𝗶𝘁𝗵 𝗺𝗲 𝘁𝗼 𝘀𝘁𝗮𝘆 𝘂𝗽𝗱𝗮𝘁𝗲𝗱! Also, check out my health AI blog here: https://lnkd.in/g3nrQFxW

Phenomenal #Proteomics #Biomarkers #TherapeuticTargets #Resource now breaking online at Cell Press | UK Biobank plasma yields comprehensive Open-Access #Proteome ↔ #Phenome #Atlas | #health | #disease | #diagnostics | Large-scale proteomics studies can refine our understanding of health and disease and enable precision medicine. Here*, the authors provide a detailed atlas of 2,920 plasma proteins linking to diseases (406 prevalent and 660 incident) and 986 health-related traits in 53,026 individuals (median follow-up: 14.8 years) from the UK Biobank, representing the most comprehensive proteome profiles to date. This atlas revealed 168,100 protein-disease associations and 554,488 protein-trait associations. Over 650 proteins were shared among at least 50 diseases, and over 1,000 showed sex and age heterogeneity. Furthermore, proteins demonstrated promising potential in disease discrimination (area under the curve [AUC] > 0.80 in 183 diseases). Finally, integrating protein quantitative trait locus data determined 474 causal proteins, providing 37 drug-repurposing opportunities and 26 promising targets with favorable safety profiles. These results provide an open-access comprehensive proteome-phenome resource (https://lnkd.in/dXGrTCbD) to help elucidate the biological mechanisms of diseases and accelerate the development of disease biomarkers, prediction models, and therapeutic targets. *https://lnkd.in/dJuTcVMg Celentyx Ltd Professor Nicholas Barnes PhD, FBPhS Omar Qureshi Catherine Brady GRAPHICAL ABSTRACT

🧬 AI just wrote the code for living organisms and they actually work. Researchers at Arc Institute and Stanford have achieved something unprecedented: using genome language models Evo 1 and Evo 2 to generate 16 viable bacteriophage genomes from scratch the first time AI has designed complete, functional genomes that work in the real world. Think about that for a moment. Not just designing a protein. Not simulating a genome on a computer. Actually creating living viral systems with substantial evolutionary novelty that infect bacteria and replicate successfully. Here's what makes this revolutionary: In 1977, ΦX174 was the first genome ever sequenced. In 2003, it was the first genome chemically synthesized. Now in 2025, it's the template for the first AI-generated genomes. We've gone from reading DNA, to writing it, to designing it. The results? Several AI-generated phages outperformed the wild-type virus, with one variant called EVO-Φ69 being 65x more powerful than natural viruses. One even uses an evolutionarily distant DNA packaging protein that researchers wouldn't have rationally designed. The implications are staggering: → Cocktails of these generated phages rapidly overcome antibiotic-resistant bacteria → Accelerated development of phage therapies for drug-resistant infections → A blueprint for designing synthetic biological systems at genome scale → Foundation for creating useful living systems with entirely novel capabilities This isn't science fiction anymore. AI models trained on 2 million bacteriophage genomes can now propose new genetic codes—and 16 out of 302 designs actually worked MIT Technology Review. We're watching the birth of generative biology in real-time. The ability to design life at the genomic level opens possibilities we're only beginning to imagine. What do you believe the opportunities and risks are of this virus making AI? The conversation is just beginning. 📄 Study: https://lnkd.in/ddP3Fjdp #SyntheticBiology #AI #GenerativeAI #Genomics #Biotechnology #Innovation #Science

We’ve stopped asking how AI can make us more efficient and started asking what becomes possible at a scale that was previously unachievable. With data, models, and compute accelerating, the new constraint is no longer access, but our ability to reason across it all. That’s why, at the AstraZeneca Centre for Genomics Research, we’re pioneering agentic systems that navigate massive datasets, interact with tools, and surface mechanistic hypotheses where literature is sparse, giving our teams a clearer, faster path to high‑value targets. It’s early, and we’re learning. In the article below, I explain why this shift from high-throughput discovery to scalable biological reasoning feels anything but incremental.

Hello everyone, It’s been a while since I’ve been active here and on my YouTube channel. Over the past few months, I’ve embarked on a steep learning curve while transitioning to a new team at Arcus - the group building institution-wide omics resources at the Children’s Hospital of Philadelphia (CHOP). The research-lab skills I brought with me needed a significant upgrade to tackle projects at this scale. Here’s what I’ve learned in the last six months: 1. Cloud-Native Data Platforms Working at an institutional level means handling massive datasets that require standardized processing. This has given me hands-on experience with several AWS services including: Amazon S3 (storage), AWS HealthOmics (genomic data processing), Athena (as a serverless SQL query engine, also learned and improved SQL skills), AWS Lambda (event-driven serverless computing), EventBridge (to build event-triggered pipelines) and ECR (to host and version custom Docker container images). 2. Advanced Workflow Orchestration I shifted from traditional HPC schedulers to Kubernetes-based systems: - Learning Argo Workflows to run container-native pipelines - Writing portable, reproducible pipelines in Nextflow and WDL This change has improved resource utilization, portability, and collaboration across teams. 3. New Cutting-Edge Genomics Platforms I am currently exploring Illumina Connected Analytics (ICA), a secure cloud-based bioinformatics platform, and leveraged DRAGEN secondary analysis pipelines to accelerate data processing by up to 10×, ensure consistency, and maintain compliance at scale. 4. Project Management with Agile & Scrum - Transitioning to an Agile framework with SCRUM methodology has transformed how I approach projects. - Sprint planning, backlog refinement, and retrospectives have provided structured ways to evaluate progress and identify improvement opportunities. - This systematic approach has enhanced both individual and team productivity by creating clear timelines and accountability. 5. Leadership & Collaboration Serving principal investigators across CHOP, I’ve led stakeholder meetings to understand project needs and delivered harmonized, standardized data products. This exposure to diverse projects has broadened my understanding of different research areas and strengthened my ability to translate technical capabilities into meaningful scientific contributions. The importance of continuously updating skills, knowledge, and experience across different platforms, technologies, and methods cannot be overstated in today's rapidly evolving technical landscape. I still have a long way to go in mastering these skills, but as they say, getting comfortable with being uncomfortable is the best way to grow. Honestly, the chance to learn new things really excites me! #Bioinformatics #Genomics #CloudComputing #Agile #Leadership #AWS #Kubernetes

UMBILICAL CORD DNA MAY PREDICT FUTURE METABOLIC HEALTH RISKS DNA changes in umbilical cord blood may help predict which children are at higher risk for future health issues like diabetes, liver disease, and stroke. Researchers analyzed chemical tags on DNA, known as methylation patterns, and linked specific alterations to markers of metabolic dysfunction later in childhood. Notably, changes in genes like TNS3, GNAS, and CSMD1 were tied to liver fat accumulation, high blood pressure, and abnormal waist-to-hip ratios. The study suggests that environmental factors during pregnancy may influence these early epigenetic signals. 3 Key Facts: 1. Early Risk Markers: Changes in DNA methylation at birth were linked to metabolic issues years later. 2. Gene Connections: Alterations in genes like TNS3 and GNAS were tied to liver fat and blood pressure problems. 3. Preventive Potential: Early detection could lead to proactive interventions before disease develops. Source: https://lnkd.in/gYkwtfvq